Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies

By G. Patel, S. Huprikar, S. Factor, S. Jenkins, D. Calfee. Infection Control & Hospital Epidemiology, 2008

887 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. (2011, background): “When outcomes for patients with CRKP are compared with those for patients with CSKP, carbapenem resistance has been independently associated with an increase in mortality [4, 5, 28].”
The negative impact of antibiotic resistance. (2016, background): “The reasons for the treatment failures associated with infections caused by resistant bacteria are probably multifactorial, but include bacterial fitness, greater severity of underlying illness [19], delays in initiation of effective therapy and in some cases a lack of effective therapy [12,26].”
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. (2012, result): “However, in their recent study of a cohort of 53 patients with KPC-Kp BSI, Zarkotou et al found no correlation between outcome and the adequacy of the initial antimicrobial regimen [15], and Patel et al reported similar findings in 99 patients with invasive infections caused by carbapenem-resistant ”
Carbapenem Resistance: A Review (2017, result): “[140] reported 38% infection-specific mortality and 48% in hospital mortality for patients infected with carbapenem-resistant Klebsiella pneumoniae isolates, contrasting with 12% and 20% for carbapenem-susceptible Klebsiella pneumoniae respectively [140].”